Phaseline

Targets › S1PR4

S1PR4 (Sphingosine 1-phosphate receptor 4): drug programs, companies and trials

2 programs from 2 companies in 9 trials: 4 Phase 2, 2 Phase 3, 2 Phase 4, 1 Phase 1; Gastroenterology, Immunology, Other; next expected readout Sep 2027.

G protein-coupled receptor highly expressed in immune cells, where it regulates immune response and cytokine production. Functions as a receptor for the lysosphingolipid sphingosine-1-phosphate (S1P). (UniProt, O95977)

Open in Phaseline: the race on S1PR4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisFingolimod
Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent
S1PR5, S1PR2, S1PR4, S1PR3, S1PR1Phase 4Multiple Sclerosis; Diabetes Mellitus, Type 2; Non Small Cell Lung CancerSep 2027
PfizerEtrasimod
Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator
S1PR1, S1PR4, S1PR5Phase 3Ulcerative Colitis; Colitis, Ulcerative; Healthy Participant; PouchitisJun 2029

Conditions

Ulcerative Colitis (2) Multiple Sclerosis (2) Colitis, Ulcerative (1) Healthy Participant (1) Pouchitis (1) Diabetes Mellitus, Type 2 (1) Non Small Cell Lung Cancer (1)

Modalities

small molecule (2)

Companies

Pfizer (1) Novartis (1)

Related targets

S1PR1 (2) S1PR5 (2) S1PR2 (1) S1PR3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.